HIMS
New shine, same pricey tag
Hims & Hers just got a Buy rating upgrade from Petri Dish Reports on April 17, and the pitch is pretty simple: if the regulatory winds keep blowing in the company’s favor, the business could keep scaling faster than the skeptics expect.
Why investors care
The big carrot here is compounded GLP-1 and peptide therapy policy. That’s the kind of regulatory backdrop that can turn into real revenue upside, especially for a company whose whole vibe is "telehealth, but make it consumer-friendly." If the rules stay supportive, Hims gets more room to build around one of its hottest growth lanes.
But the market still has receipts
The report also basically admits the stock isn’t cheap. With a P/E of 55.22, Hims is still trading like a company investors believe has plenty of runway left. That can work beautifully right up until it doesn’t, which is why valuation remains the other shoe hanging over the story.
Insider vibes aren’t exactly euphoric
One wrinkle: insiders have sold about $3.4 million of Hims shares over the past three months, with no offsetting buying. That doesn’t automatically scream trouble, but it does add a little side-eye to the bullish narrative.
Big picture: Hims is still a story stock with real momentum, but now the debate is less about whether people want the product and more about whether the current price already assumes the good news keeps rolling in.